Gilead Yeztugo has been a victory in the fight against the virus, but its high prices bring concerns.
The United States Product and Drug Office has officially approved the yeztugo injection for HIV prevention, Sciencealert reports. The drug developed by Gilead Sciences is administered twice a year and, given its effectiveness, is a real success in the fight against the human immunodeficiency virus.
The real name of the drug is Lenacapavir, but it will be sold under the commercial name Yeztugo. During clinical education in adults and adolescents, he showed the effectiveness of more than 99.9%.
Despite the effectiveness, experts’ optimism is probably a high cost. A similar drug – a Cabotravir that is introduced every two months – worth thousands of dollars a year and still not prevalent. It is expected that the starting price of yeztugo in the United States can be up to 25 thousand per year, although avoiding use should be less than 39 thousand – the current cost of Lenakapavir treatment rate.
Human rights researchers and activists urged Gilead to significantly reduce prices to overcome the HIV epidemic.
In October, Gilead himself entered into agreements with six pharmaceutical companies for the manufacture and distribution of drugs to 120 countries with low and medium income. In addition, the company joins the Global Fund and PEPFAR Program in doses for two million people. However, the reduction in PEPFAR financing under the Donald Trump administration doubts the long -term prospects of this initiative.
Know how many cases of HIV infection have been recorded in Ukraine since the beginning of the year
News from CORRESPONDENT.NET On the telegram and whatsapp. Subscribe to our channels https://t.me/KorresPondentNet and WhatsApp
Source: korrespondent
I am Ben Stock, a passionate and experienced digital journalist working in the news industry. At the Buna Times, I write articles covering technology developments and related topics. I strive to provide reliable information that my readers can trust. My research skills are top-notch, as well as my ability to craft engaging stories on timely topics with clarity and accuracy.